These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

261 related items for PubMed ID: 23364873

  • 1. Parental perceived benefits of OROS-methylphenidate treatment for the child with attention-deficit/hyperactivity disorder and for parents themselves.
    Kim JW, Park S, Kim BN, Shin MS, Cho SC, Kim JH, Son JW, Shin YM, Chung US, Han DH.
    Pharmacopsychiatry; 2013 Jun; 46(4):137-46. PubMed ID: 23364873
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Better efficacy for the osmotic release oral system methylphenidate among poor adherents to immediate-release methylphenidate in the three ADHD subtypes.
    Chou WJ, Chou MC, Tzang RF, Hsu YC, Gau SS, Chen SJ, Wu YY, Huang YF, Liang HY, Cheng H.
    Psychiatry Clin Neurosci; 2009 Apr; 63(2):167-75. PubMed ID: 19335386
    [Abstract] [Full Text] [Related]

  • 4. Osmotic Release Oral System Methylphenidate Versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder in Chinese Youth: 8-Week Comparative Efficacy and 1-Year Follow-Up.
    Su Y, Yang L, Stein MA, Cao Q, Wang Y.
    J Child Adolesc Psychopharmacol; 2016 May; 26(4):362-71. PubMed ID: 26779845
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
    Newcorn JH, Nagy P, Childress AC, Frick G, Yan B, Pliszka S.
    CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198
    [Abstract] [Full Text] [Related]

  • 8. Effects of Atomoxetine and Osmotic Release Oral System-Methylphenidate on Executive Functions in Patients with Combined Type Attention-Deficit/Hyperactivity Disorder.
    Ince Tasdelen B, Karakaya E, Oztop DB.
    J Child Adolesc Psychopharmacol; 2015 Aug; 25(6):494-500. PubMed ID: 26218871
    [Abstract] [Full Text] [Related]

  • 9. An Open-Label, Randomized Trial of Methylphenidate and Atomoxetine Treatment in Children with Attention-Deficit/Hyperactivity Disorder.
    Shang CY, Pan YL, Lin HY, Huang LW, Gau SS.
    J Child Adolesc Psychopharmacol; 2015 Sep; 25(7):566-73. PubMed ID: 26222447
    [Abstract] [Full Text] [Related]

  • 10. Academic, behavioral, and cognitive effects of OROS® methylphenidate on older children with attention-deficit/hyperactivity disorder.
    Wigal SB, Wigal T, Schuck S, Brams M, Williamson D, Armstrong RB, Starr HL.
    J Child Adolesc Psychopharmacol; 2011 Apr; 21(2):121-31. PubMed ID: 21488750
    [Abstract] [Full Text] [Related]

  • 11. Efficacy of osmotic-release oral system (OROS) methylphenidate for mothers with attention-deficit/hyperactivity disorder (ADHD): preliminary report of effects on ADHD symptoms and parenting.
    Chronis-Tuscano A, Seymour KE, Stein MA, Jones HA, Jiles CD, Rooney ME, Conlon CJ, Efron LA, Wagner SA, Pian J, Robb AS.
    J Clin Psychiatry; 2008 Dec; 69(12):1938-47. PubMed ID: 19192455
    [Abstract] [Full Text] [Related]

  • 12. Does OROS-methylphenidate improve core symptoms and deficits in executive function? Results of an open-label trial in adults with attention deficit hyperactivity disorder.
    Fallu A, Richard C, Prinzo R, Binder C.
    Curr Med Res Opin; 2006 Dec; 22(12):2557-66. PubMed ID: 17166338
    [Abstract] [Full Text] [Related]

  • 13. Randomized controlled trial of osmotic-release methylphenidate with cognitive-behavioral therapy in adolescents with attention-deficit/hyperactivity disorder and substance use disorders.
    Riggs PD, Winhusen T, Davies RD, Leimberger JD, Mikulich-Gilbertson S, Klein C, Macdonald M, Lohman M, Bailey GL, Haynes L, Jaffee WB, Haminton N, Hodgkins C, Whitmore E, Trello-Rishel K, Tamm L, Acosta MC, Royer-Malvestuto C, Subramaniam G, Fishman M, Holmes BW, Kaye ME, Vargo MA, Woody GE, Nunes EV, Liu D.
    J Am Acad Child Adolesc Psychiatry; 2011 Sep; 50(9):903-14. PubMed ID: 21871372
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and tolerability of OROS methylphenidate in Korean children with attention-deficit/hyperactivity disorder.
    Lee SI, Hong SD, Kim SY, Kim EJ, Kim JH, Kim JH, Park MK, Park S, Park JH, Oh EY, Lim TS, Cheong S, Cho IH, Choi JW.
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jan 30; 31(1):210-6. PubMed ID: 17046131
    [Abstract] [Full Text] [Related]

  • 15. Baseline severity of parent-perceived inattentiveness is predictive of the difference between subjective and objective methylphenidate responses in children with attention-deficit/hyperactivity disorder.
    Park S, Kim BN, Cho SC, Kim JW, Shin MS, Yoo HJ, Han DH, Cheong JH.
    J Child Adolesc Psychopharmacol; 2013 Aug 30; 23(6):410-4. PubMed ID: 23952188
    [Abstract] [Full Text] [Related]

  • 16. An Open-label, Self-control, Prospective Study on Cognitive Function, Academic Performance, and Tolerability of Osmotic-release Oral System Methylphenidate in Children with Attention-deficit Hyperactivity Disorder.
    Zheng Y, Liang JM, Gao HY, Yang ZW, Jia FJ, Liang YZ, Fang F, Li R, Xie SN, Zhuo JM.
    Chin Med J (Engl); 2015 Nov 20; 128(22):2988-97. PubMed ID: 26608976
    [Abstract] [Full Text] [Related]

  • 17. Transitioning to OROS(®) methylphenidate from atomoxetine is effective in children and adolescents with ADHD.
    Niederkirchner K, Slawik L, Wermelskirchen D, Rettig K, Schäuble B.
    Expert Rev Neurother; 2011 Apr 20; 11(4):499-508. PubMed ID: 21469923
    [Abstract] [Full Text] [Related]

  • 18. OROS-methylphenidate efficacy on specific executive functioning deficits in adults with ADHD: a randomized, placebo-controlled cross-over study.
    Bron TI, Bijlenga D, Boonstra AM, Breuk M, Pardoen WF, Beekman AT, Kooij JJ.
    Eur Neuropsychopharmacol; 2014 Apr 20; 24(4):519-28. PubMed ID: 24508533
    [Abstract] [Full Text] [Related]

  • 19. Exploring the impact of once-daily OROS® methylphenidate (MPH) on symptoms and quality of life in children and adolescents with ADHD transitioning from immediate-release MPH.
    Kordon A, Stollhoff K, Niederkirchner K, Mattejat F, Rettig K, Schäuble B.
    Postgrad Med; 2011 Sep 20; 123(5):27-38. PubMed ID: 21904084
    [Abstract] [Full Text] [Related]

  • 20. Outcomes of OROS methylphenidate compared with atomoxetine in children with ADHD: a multicenter, randomized prospective study.
    Kemner JE, Starr HL, Ciccone PE, Hooper-Wood CG, Crockett RS.
    Adv Ther; 2005 Sep 20; 22(5):498-512. PubMed ID: 16418159
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.